Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Status:
Recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of pegylated liposomal
doxorubicin（PLD）plus Albumin-Bound Paclitaxel and trastuzumab as neoadjuvant therapy in HER-2
positive breast cancer.